Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 4;21(15):e882-e885.
doi: 10.4244/EIJ-D-24-00902.

Long-term predictors of target vessel failure after intracoronary lithotripsy: 12-month results from the France LILI registry

Benjamin Honton  1 , Hakim Benamer  2 , Benoit Lattuca  3 , Thibault Lhermusier  4 , Nicolas Amabile  2   5 , Frederic Marco  6 , Janusz Lipiecki  7 , Ashok Tirouvanziam  8 , Julien Jeanneteau  9 , Eric Van Belle  10 , Alexandre Canville  11 , Grégoire Rangé  12 , Matthieu Périer  13 , Jacques Monsegu  14 , Thomas Cuisset  15 , Géraud Souteyrand  16 , Gonzalo Quaino  17 , Marine Quillot  18 , Gael Bouchou  19 , Fabrice Leroy  20 , Christophe Saint Etienne  21 , Sebastien Levesque  22 , Antoine Gommeaux  23 , Antoine Gerbay  24 , Benjamin Seguy  25 , Benjamin Fialon  26 , Julien Adjedj  27 , Louis-Marie Desroche  28 , Luc Maillard  29 , Nicolas Lhoest  30 , Olivier Darremont  31 , Martine Gilard  32 , Edouardo Aptecar  33 , Pascal Motreff  16 , Vincent Bataille  34 , Philippe Commeau  35 , Guillaume Cayla  3
Affiliations

Long-term predictors of target vessel failure after intracoronary lithotripsy: 12-month results from the France LILI registry

Benjamin Honton et al. EuroIntervention. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

B. Honton reports consulting fees from Medtronic, Abbott, and Boston Scientific; and lecture honorarium from Medtronic, Shockwave Medical, Abbott, and Boston Scientific. B. Lattuca reports consulting fees from Terumo, Abbott, and Boston Scientific; lecture honorarium from Medtronic, Amarin, and AstraZeneca; and scientific grants from Biotronik and Boston Scientific. T. Lhermusier reports consulting fees and honorarium from Medtronic, Abbott, and Edwards Lifesciences. N. Amabile reports consulting fees from GE HealthCare, Shockwave Medical, Abbott, and Boston Scientific; lecture honorarium from Shockwave Medical, Abbott, and Boston Scientific; and institutional grants from Abbott. J. Jeanneteau reports consulting honorarium from BMS, AstraZeneca, Pfizer, and Novo Nordisk. G. Rangé reports consulting fees from MicroPort, Shockwave Medical, Abbott, Boston Scientific, and Terumo. J. Monsegu reports consulting fees from Abbott and Terumo. T. Cuisset reports consulting fees from Medtronic, Abbott, and Boston Scientific; lecture honorarium from Shockwave Medical, Terumo, Edwards Lifesciences, Europa, and Sanofi; and is a shareholder in CERC. G. Souteyrand reports consulting fees and honorarium from Medtronic, Terumo, Abbott, Boston Scientific, and B. Braun. M. Quillot reports consulting fees and honorarium from Shockwave Medical, Boston Scientific, and Sanofi. C. Saint Etienne reports honorarium from Medtronic, Abbott, Biotronik, and Edwards Lifesciences. S. Levesque reports honorarium from Shockwave Medical. A. Gerbay reports consulting fees from Abbott; honorarium from Biosensors; and is a shareholder in Inari. B. Seguy reports consulting fees from Boston Scientific; and honorarium from Biosensors and Boston Scientific. J. Adjedj reports consulting fees and honorarium from Shockwave Medical. O. Darremont reports honorarium from Abbott, Boston Scientific, and Edwards Lifesciences. P. Motreff reports consulting fees and honorarium from Terumo, Abbott, and Boston Scientific. P. Commeau reports consulting fees from Edwards Lifesciences, Abbott, Boston Scientific, and SMT; and is a shareholder in Edwards Lifesciences. G. Cayla reports consulting fees from Edwards Lifesciences, Abbott, Medtronic, MicroPort, and Com&Co; and honorarium from Pfizer/BMS, and Biotronik. The other authors have no conflicts of interest to declare.

References

    1. Dini CS, Tomberli B, Mattesini A, Ristalli F, Valente S, Stolcova M, Meucci F, Baldereschi G, Fanelli F, Shlofmitz RA, Ali ZA, Di Mario. Intravascular lithotripsy for calcific coronary and peripheral artery stenoses. EuroIntervention. 2019;15:714–21. - PubMed
    1. Hill JM, Kereiakes DJ, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, Herrmann HC, Bachinsky W, Waksman R, Stone GW Disrupt CAD III Investigators. Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. J Am Coll Cardiol. 2020;76:2635–46. - PubMed
    1. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chuang YC, Ditrano CJ, Leon MB. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995;91:1959–65. - PubMed
    1. Ali ZA, Kereiakes D, Hill J, Saito S, Di Mario, Honton B, Gonzalo N, Riley R, Maehara A, Matsumura M, Stone GW, Shlofmitz R. Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Calcified Nodules. JACC Cardiovasc Interv. 2023;16:1122–4. - PubMed
    1. McInerney A, Travieso A, Jerónimo Baza, Alfonso F, Del Val, Cerrato E, Garcia de, Pinar E, Perez de, Jimenez Quevedo, Tirado-Conte G, Nombela-Franco L, Brugaletta S, Cepas-Guillén P, Sabaté M, Cubero Gallego, Vaquerizo B, Jurado A, Varbella F, Jimenez M, Garcia Escobar, de la, Amat Santos, Jimenez Diaz, Escaned J, Gonzalo N. Impact of coronary calcium morphology on intravascular lithotripsy. EuroIntervention. 2024;20:e656–68. - PMC - PubMed

LinkOut - more resources